|
Molecular biomarkers
|
HGSC
|
CCC
|
|---|
| |
Platinum sensitive (%)
|
aPlatinum resistant (%)
|
HGSCP
|
Platinum sensitive (%)
|
aPlatinum resistant (%)
|
CCC P
|
|---|
|
EGFR
| | |
0.365
| | |
0.129
|
|
Negative
|
58(75.3)
|
20(66.7)
| |
36(58.1)
|
17(77.3)
| |
|
Positive
|
19(24.7)
|
10(33.3)
| |
26(41.9)
|
5(22.7)
| |
|
HER2
| | |
1.000
| | |
0.725
|
|
Negative
|
75(97.4)
|
29(96.7)
| |
56(87.5)
|
19(82.6)
| |
|
Positive
|
2(2.6)
|
1(3.3)
| |
8(12.5)
|
4(17.4)
| |
|
PTEN
| | |
0.530
| | |
0.679
|
|
Negative
|
68(88.3)
|
25(83.3)
| |
58(92.1)
|
21(87.5)
| |
|
Positive
|
9(11.7)
|
5(16.7)
| |
5(7.9)
|
3(12.5)
| |
|
AURKA
| | |
0.505
| | |
0.042
|
|
Negative
|
49(63.6)
|
17(56.7)
| |
42(65.6)
|
10(41.7)
| |
|
Positive
|
28(36.3)
|
13(43.3)
| |
22(34.4)
|
14(58.3)
| |
|
BRCA1
| | |
0.584
| | |
0.848
|
|
Negative
|
55(71.4)
|
23(76.7)
| |
35(56.5)
|
13(54.2)
| |
|
Positive
|
22(28.6)
|
7(23.3)
| |
27(43.5)
|
11(45.8)
| |
|
BRCA2
| | |
1.000
| | |
0.542
|
|
Negative
|
68(88.3)
|
27(90.0)
| |
50(80.6)
|
21(87.5)
| |
|
Positive
|
9(11.7)
|
3(10.0)
| |
12(19.4)
|
3(12.5)
| |
|
PD-L1
| | |
0.502
| | |
0.028
|
|
Negative
|
66(86.8)
|
28(93.3)
| |
56(87.5)
|
15(65.2)
| |
|
Positive
|
10(13.2)
|
2(6.7)
| |
8(12.5)
|
8(34.8)
| |
- There are 107 cases of HGSC and 88 cases of CCC having both primary tumor immunohistochemistry results and information of chemotherapy. However, the total number for each antibody does not add to up 107 and 88, respectively
-
aInterval time <6 months from completion of last platinum-based chemotherapy to disease recurrence
- Bold value denotes P with statistical significance
